Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accounts Payables: 2024-2025

Historic Accounts Payables for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $66.8 million.

  • Kura Oncology's Accounts Payables rose 80.67% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 80.67%. This contributed to the annual value of $50.0 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Accounts Payables stood at $66.8 million for Q3 2025, which was up 26.18% from $52.9 million recorded in Q2 2025.
  • Kura Oncology's Accounts Payables' 5-year high stood at $66.8 million during Q3 2025, with a 5-year trough of $30.9 million in Q1 2024.